Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Open Access
- 1 March 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 20 (3), 655-664
- https://doi.org/10.1681/asn.2008050482
Abstract
Despite the first-line use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), there is still a large need to improve the prevention and progression of diabetic nephropathy and its associated cardiovascular events. Endothelin antagonists have shown anti-inflammatory, antifibrotic, and antiproteinuric effects in experimental studies. This study was a randomized, placebo-controlled, double-blind, parallel-design, dosage-range study of the effect of the endothelin-A antagonist avosentan (SPP301) on urinary albumin excretion rate (UAER) in patients with diabetic nephropathy. We randomly assigned 286 patients with diabetic nephropathy, macroalbuminuria (UAER 0.2 to 5.6 mg/min), and BP <180/110 mmHg to 12 wk of avosentan (5, 10, 25, and 50 mg) or placebo, in addition to standard ACEI/ARB therapy. Relative to baseline, all avosentan dosages decreased mean relative UAER (−16.3 to −29.9%) compared with placebo (35.5%). Median relative UAER decreased with all avosentan dosages (−28.7 to −44.8%) compared with placebo (12.1%). Creatinine clearance and BP were unchanged at 12 wk. The main adverse events were peripheral edema (12%), mainly with high (≥25 mg) dosages of avosentan; significant increases in liver enzymes did not occur. Twenty-one (7.3%) patients experienced adverse events that led to withdrawal from study medication. In summary, the endothelin-A antagonist avosentan given in addition to standard ACEI/ARB treatment decreases UAER in patients with diabetic nephropathy and macroalbuminuria.Keywords
This publication has 41 references indexed in Scilit:
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney DiseaseAmerican Journal of Kidney Diseases, 2007
- Endothelin A Receptor Blockade Reduces Diabetic Renal Injury via an Anti-Inflammatory MechanismJournal of the American Society of Nephrology, 2007
- Role of endothelin and endothelin receptor antagonists in renal diseaseEuropean Journal of Clinical Investigation, 2006
- Renal Protection in Hypertensive Patients: Selection of Antihypertensive TherapyDrugs, 2005
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Meetings and Conferences · Tagungen und KongresseOncology Research and Treatment, 2003
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Circulating Endothelin-1 in Non-Insulin-Dependent Diabetic Patients with RetinopathyHormone and Metabolic Research, 1997
- Metabolic effects of converting enzyme inhibitors: Focus on the reduction of cholesterol and lipoprotein(a) by fosinoprilThe American Journal of Cardiology, 1993